Lundbeck drug hope moves closer to moment of truth

This quarter, pharmaceutical company Lundbeck will deliver crucial results for Rexulti in a new indication. The market awaits the news with anticipation, since share prices could skyrocket.
Lundbeck CEO Deborah Dunsire | Photo: Gregers Tycho/ERH
Lundbeck CEO Deborah Dunsire | Photo: Gregers Tycho/ERH
BY BENJAMIN WERNER CHRISTENSEN, TRANSLATED BY NIELSINE NIELSEN

A hopeful market led Lundbeck's share price to briefly gain momentum, but the slight boost evaporated again just as quickly.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading